Evidence map›Paper›PMID 39198400›Full record

ArticleBlood cancer journal2024

B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation.

Lisa Pfeuffer, Viola Siegert, Julia Frede, Leonie Rieger, Riccardo Trozzo, Niklas de Andrade Krätzig, Sandra Ring, Shamim Sarhadi, Nicole Beck, Stefan Niedermeier and 11 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lisa PfeufferInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0003-4962-7755
Viola SiegertInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0009-0001-4649-3336
Julia FredeGerman Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
Leonie RiegerTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Riccardo TrozzoTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.ORCID 0000-0002-5889-994X
Niklas de Andrade KrätzigTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.ORCID 0000-0003-2141-6745
Sandra RingInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Shamim SarhadiInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Nicole BeckInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Stefan NiedermeierInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0009-0009-3757-2081
Mar Abril-GilInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Mohamed ElbahloulTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Marianne RemkeInstitute of Pathology, Technical University Munich, Munich, Germany.
Katja SteigerGerman Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
Ruth EichnerTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.ORCID 0000-0002-8433-9452
Julia JellusovaInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Roland RadTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Florian BassermannTranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany.ORCID 0000-0003-4435-2609
Christof WinterInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Jürgen RulandInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0002-8381-3597
Maike BuchnerInstitute of Clinical Chemistry and Pathobiochemistry, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. maike.buchner@tum.de.ORCID 0000-0002-4196-096X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 2851/6-1Deutsche Forschungsgemeinschaft (German Research Foundation) 505372148Deutsche Forschungsgemeinschaft (German Research Foundation) 516923543Deutsche Forschungsgemeinschaft (German Research Foundation) BA 2851/7-1Deutsche Krebshilfe (German Cancer Aid) 70114720Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2018.111.1
6 · The paper itself

Abstract

B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), remain incurable, with MM particularly prone to relapse. Our study introduces a novel mouse model with active RANK signaling and the TCL1 oncogene, displaying both CLL and MM phenotypes. In younger mice, TCL1 and RANK expression expands CLL-like B1-lymphocytes, while MM originates from B2-cells, becoming predominant in later stages and leading to severe disease progression and mortality. The induced MM mimics human disease, exhibiting features like clonal plasma cell expansion, paraproteinemia, anemia, and kidney and bone failure, as well as critical immunosurveillance strategies that promote a tumor-supportive microenvironment. This research elucidates the differential impacts of RANK activation in B1- and B2-cells and underscores the distinct roles of single versus combined oncogenes in B-cell malignancies. We also demonstrate that human MM cells express RANK and that inhibiting RANK signaling can reduce MM progression in a xenotransplantation model. Our study provides a rationale for further investigating the effects of RANK signaling in B-cell transformation and the shaping of a tumor-promoting microenvironment.

Indexed as

B-LymphocytesCell Transformation, NeoplasticMultiple MyelomaProto-Oncogene ProteinsSignal TransductionAnimalsCell LineageDisease Models, AnimalHumansLeukemia, Lymphocytic, Chronic, B-CellMiceReceptor Activator of Nuclear Factor-kappa BTumor MicroenvironmentProto-Oncogene ProteinsReceptor Activator of Nuclear Factor-kappa BTCL1A protein, humanTcl1 protein, mouseTNFRSF11A protein, humanTnfrsf11a protein, mouse

Identifiers

PMID39198400
PMCPMC11358282

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.